ritlecitinib (Litfulo) Report issue

Small molecule Approved FDA
AACT PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C
  • InChIKey: CBRJPFGIXUFMTM-WDEREUQCSA-N
  • Mol. Mass: 285.35
  • ALogP: 1.94
  • ChEMBL Molecules:
    ritlecitinib  
    ritlecitinib tosylate  
More Chemistry

Pharmacology

Alternative names

pf-06651600

Organizations (4)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (16)

Approved Indications (1)


 

Alopecia Areata (approved 2023)

Experimental Indications - Clinical Trial Phases 1-4 (16)


 

Adult (Phase 1)

Alopecia (Phase 2)

Alopecia Areata (Phase 3)

Arthritis, Rheumatoid (Phase 2)

Celiac Disease (Phase 2)

Colitis, Ulcerative (Phase 2)

Crohn Disease (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Healthy Volunteers (Phase 1)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 1)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Mycosis Fungoides (Phase 2)

Pharmacokinetics (Phase 1)

Sezary Syndrome (Phase 2)

Vitiligo (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 42
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue